| Overall survival |  | Progression free survival | |||
---|---|---|---|---|---|---|
 | HR | 95% CI | P | HR | 95% CI | P |
FIGO stage (early stage vs. advanced stage) | 1.127 | 0.357–3.562 | 0.838 | 1.744 | 0.576–5.288 | 0.325 |
Histologic grade (well vs. poor and moderate) | 0.615 | 0.256–1.475 | 0.276 | 0.904 | 0.393–2.077 | 0.811 |
Ascites (no vs. yes) | 0.850 | 0.381–1.897 | 0.692 | 0.667 | 0.337–1.323 | 0.247 |
LN metastasis (no vs. yes) | 0.924 | 0.460–1.856 | 0.823 | 0.786 | 0.410–1.506 | 0.468 |
Age (≤50 vs. >50 years) | 2.920 | 1.466–5.815 | 0.002 | 2.403 | 1.302–4.435 | 0.005 |
Preoperative CA125 (U/ml) (≤600 vs. >600) | 0.548 | 0.280–1.073 | 0.079 | 0.327 | 0.177–0.607 | 0.000 |
DOT1L expression (low vs. high) | 4.705 | 2.160–10.248 | 0.000 | 8.884 | 3.974–19.861 | 0.000 |